Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

NCT02083068 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: Vaccine PvCS N+C+R
BIOLOGICAL: Vaccine PvCS N+C
BIOLOGICAL: SSN Montanide ISA-51

Sponsor

Malaria Vaccine and Drug Development Center

Collaborators

[object Object]